White Paper

Asia Pacific As A Clinical Trials Powerhouse

Source: Citeline

By Dr Annie Siu, PhD, MBA, APAC Content Director, Citeline, and Andy Benson, MSc, Senior Director, Trialtrove

Asia iStock-1190455899

It is often said that “disease knows no borders,” but is the same true for clinical development?

Patient availability is a critical component for clinical trials, and so it stands to reason that clinical development should match the epidemiology of diseases. Of course, this is often not the case, with longstanding biases towards studies in the US and Europe, where healthcare infrastructure and the pharmaceutical market are generally more mature. However, change is underway.

This whitepaper takes a deep dive into the clinical trial landscape in the Asia-Pacific (APAC) region over the past decade, from 2012 to 2021. It shows that during this time period, APAC has become a hotspot for clinical trials, with trial activity trending upwards and eventually contributing almost half of the entire global clinical trial activity in 2021. Interestingly, each APAC location has its own driving forces and unique differentiators. Utilizing the gold-standard clinical trial intelligence database Trialtrove, this new analysis delves into the sponsors, diseases, and types of trials across the APAC region, and considers the factors shaping the present-day landscape in those APAC locations with the highest overall trial activity.

As we navigate through the data, it is important to note three things. Firstly, Trialtrove is focused on drug clinical trials with a prospective time perspective. Other types of studies, for example those evaluating devices, surgical, or behavioral interventions, or based on retrospective data, are not part of this analysis. Secondly, trial start numbers are limited to those for which an actual start date is provided in the public domain (i.e. we excluded trials listed as planned and never confirmed to have started, or for which a specific actual start date was never disclosed). The numbers for recent years may also be impacted by delayed reporting of trial activity. Thirdly, we are considering the APAC region to consist of the locations classified into the “Asia” and “Australia/Oceania” Trial Regions in Trialtrove.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader